Epigenetic Aging ·
This study explores the effects of metformin on the epigenetic clock in older, non-diabetic individuals living with HIV. Metformin, a drug primarily used to manage type 2 diabetes, has garnered attention for its potential geroprotective properties. This research aims to understand whether metformin can influence biological aging as measured by epigenetic biomarkers in a specific population.
What this study examined
The METFORAGING trial was a single-centre, double-blind, randomised, parallel-group, placebo-controlled pilot study conducted in Madrid, Spain. It involved non-diabetic individuals aged 50 years or older, living with HIV, and who had maintained a stable antiretroviral regimen with an undetectable viral load for at least 12 months. Participants were randomly assigned to receive either 850 mg of oral metformin or a matching placebo twice daily for a duration of 96 weeks. The primary outcome was the adjusted difference in epigenetic age acceleration (EAA) as measured by the PhenoAge clock at week 96.
Why this matters for longevity research
Understanding how interventions like metformin can impact the epigenetic clock is crucial for longevity research. The epigenetic clock serves as a biomarker for biological age, which can differ significantly from chronological age. By studying older adults living with HIV, this research addresses a population that may experience accelerated aging due to chronic inflammation and immune system decline. If metformin can effectively modify biological aging, it may have broader implications for enhancing healthspan in various aging populations.
Key findings
- The trial included 40 participants, with a median age of 56.4 years.
- Participants were randomly assigned to metformin (n = 19) or placebo (n = 21).
- Adherence to the treatment regimen was high, with a mean adherence of 97.5% in both groups.
- At week 96, the adjusted between-group difference for PhenoAge EAA was -1.02 years, indicating no significant difference between the metformin and placebo groups.
- Adverse events were reported in both groups, but no serious adverse events were attributed to metformin.
- The study supports the feasibility of conducting geroscience trials in populations living with HIV.
- Further research is needed with larger sample sizes to confirm these preliminary findings.
The science behind it
Metformin's potential effects on the epigenetic clock may be linked to its role in cellular metabolism and its ability to activate AMPK (AMP-activated protein kinase). AMPK is a key regulator of energy homeostasis and has been implicated in promoting autophagy, a process that clears damaged cellular components. Additionally, metformin may influence the sirtuin pathway, which is associated with longevity and metabolic regulation. These mechanisms align with the emerging understanding of the biology of aging, where interventions targeting metabolic pathways could potentially extend healthspan.
How it fits into the longevity field
This study contributes to a growing body of literature examining the role of metformin in aging and longevity. Previous research has suggested that metformin may have benefits beyond glycemic control, including effects on inflammation and cellular aging. Other interventions, such as caloric restriction and NAD+ precursors, have also been studied for their potential to influence the epigenetic clock and biological aging. The exploration of metformin in diverse populations, such as those living with HIV, helps to broaden the understanding of its geroprotective potential.
Practical takeaways
Researchers and informed readers should note that while this study provides preliminary insights into metformin's effects on the epigenetic clock, the findings are not conclusive. The lack of significant differences between the metformin and placebo groups suggests that further investigation is warranted. Larger, adequately powered studies will be essential to determine whether metformin can effectively modify biological aging in various populations, including those with chronic health conditions.
FAQ
What is the epigenetic clock?
The epigenetic clock is a biomarker that estimates biological age based on DNA methylation patterns, which can differ from chronological age.
How does metformin affect aging?
Metformin may influence aging through mechanisms such as activating AMPK, promoting autophagy, and potentially impacting the sirtuin pathway.
Why study metformin in people living with HIV?
Individuals living with HIV may experience accelerated aging due to chronic inflammation, making them a relevant population for studying geroprotective interventions like metformin.
Source: PubMed · EClinicalMedicine · published 2026-05-01.